Cipla | CIPLA - Operating Expenses


Cipla reported INR63.61B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Arca Biopharma USD 36.43M 2M Mar/2026
aTyr Pharma USD 2.55M 126.72K Jun/2026
Bio Path USD 297K 191K Mar/2026
Brainstorm Cell Therapeutics USD 2.05M 198K Mar/2026
Capricor Therapeutics USD 29.16M 2.87M Dec/2025
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Cipla INR 63.61B 1.3B Sep/2026
Dr.Reddys Laboratories INR 74.82B 2.93B Sep/2026
Immunic USD 23.33M 2.67M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sun Pharmaceuticals INR 122.92B 5.49B Sep/2026
TherapeuticsMD USD 1.41M 50K Jun/2024
UPL INR 103.67B 8.54B Sep/2026